About GlycoMimetics (NASDAQ:GLYC)
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GLYC
CUSIPN/A
Phone240-243-1201
Debt
Debt-to-Equity RatioN/A
Current Ratio15.57%
Quick Ratio15.57%
Price-To-Earnings
Trailing P/E Ratio-15.32
Forward P/E Ratio-17.14
P/E GrowthN/A
Sales & Book Value
Annual Sales$20,000.00
Price / Sales36,775.10
Cash FlowN/A
Price / CashN/A
Book Value$3.49 per share
Price / Book4.96
Profitability
EPS (Most Recent Fiscal Year)($1.13)
Net Income$-33,280,000.00
Net MarginsN/A
Return on Equity-35.45%
Return on Assets-33.02%
Miscellaneous
Employees40
Outstanding Shares42,490,000
GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions
What is GlycoMimetics' stock symbol?
GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
How were GlycoMimetics' earnings last quarter?
GlycoMimetics Inc (NASDAQ:GLYC) released its earnings results on Tuesday, March, 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.01. View GlycoMimetics' Earnings History.
What price target have analysts set for GLYC?
6 brokerages have issued 1-year price objectives for GlycoMimetics' shares. Their forecasts range from $12.00 to $35.00. On average, they anticipate GlycoMimetics' stock price to reach $25.00 in the next year. View Analyst Ratings for GlycoMimetics.
Who are some of GlycoMimetics' key competitors?
Some companies that are related to GlycoMimetics include Prothena (PRTA), Impax Laboratories (IPXL), Zogenix (ZGNX), Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN), Immuron (IMRN), Myovant Sciences (MYOV), Theravance Biopharma (TBPH), G1 Therapeutics (GTHX), Apellis Pharmaceuticals (APLS), Endo International (ENDP), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD), PTC Therapeutics (PTCT), Revance Therapeutics (RVNC), Mallinckrodt (MNK), WAVE Life Sciences (WVE) and Epizyme (EPZM).
Who are GlycoMimetics' key executives?
GlycoMimetics' management team includes the folowing people:
- Mrs. Rachel K. King, CEO & Director (Age 59)
- Mr. Brian M. Hahn, CFO & Sec. (Age 44)
- Dr. John L. Magnani Ph.D., Sr. VP of Research, Chief Scientific Officer & Director (Age 65)
- Dr. Helen M. Thackray M.D., FAAP, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 50)
- Mr. Henry Flanner, VP of Technical Operations
Has GlycoMimetics been receiving favorable news coverage?
News articles about GLYC stock have been trending somewhat positive on Thursday, Accern reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GlycoMimetics earned a media sentiment score of 0.04 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.21 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of GlycoMimetics?
Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GlycoMimetics' stock price today?
One share of GLYC stock can currently be purchased for approximately $17.31.
How big of a company is GlycoMimetics?
GlycoMimetics has a market capitalization of $754.65 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-33,280,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. GlycoMimetics employs 40 workers across the globe.
How can I contact GlycoMimetics?
GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]
MarketBeat Community Rating for GlycoMimetics (GLYC)
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
GlycoMimetics (NASDAQ:GLYC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for GlycoMimetics in the last 12 months. Their average twelve-month price target is $25.00, suggesting that the stock has a possible upside of 44.43%. The high price target for GLYC is $35.00 and the low price target for GLYC is $12.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $25.00 | $25.00 | $22.60 | $14.75 |
| Price Target Upside: | 44.43% upside | 37.14% upside | 44.13% upside | 8.78% upside |
GlycoMimetics (NASDAQ:GLYC) Consensus Price Target History
GlycoMimetics (NASDAQ:GLYC) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
GlycoMimetics (NASDAQ:GLYC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
GlycoMimetics (NASDAQ GLYC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 43.80%
Institutional Ownership Percentage: 77.02%
GlycoMimetics (NASDAQ GLYC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/8/2017 | Helen M Thackray | SVP | Sell | 2,000 | $15.01 | $30,020.00 | 148,615 |  |
| 9/18/2017 | Helen M Thackray | SVP | Sell | 2,000 | $13.00 | $26,000.00 | 150,615 | |
| 5/25/2017 | Helen M Thackray | SVP | Sell | 2,000 | $15.57 | $31,140.00 | 152,615 | |
| 5/19/2017 | Helen M Thackray | SVP | Sell | 2,000 | $12.14 | $24,280.00 | 154,615 | |
| 12/20/2016 | Daniel M. Junius | Director | Buy | 5,000 | $6.01 | $30,050.00 | | |
| 10/3/2016 | Helen M Thackray | VP | Sell | 4,000 | $7.00 | $28,000.00 | 156,715 | |
| 7/20/2016 | Helen M Thackray | VP | Sell | 2,000 | $8.00 | $16,000.00 | 160,615 | |
| 7/6/2016 | Helen M Thackray | CMO | Sell | 22,000 | $7.00 | $154,000.00 | 179,547 | |
| 3/4/2016 | Mark Alan Goldberg | Director | Buy | 10,397 | $4.77 | $49,593.69 | 11,497 | |
| 12/22/2014 | Michael A Henos | Director | Sell | 21,257 | $8.52 | $181,109.64 | | |
| 12/17/2014 | Michael A Henos | Director | Sell | 6,725 | $8.97 | $60,323.25 | | |
| 12/15/2014 | Michael A Henos | Director | Sell | 1,604 | $8.98 | $14,403.92 | | |
| 6/13/2014 | Michael A Henos | Director | Buy | 11,000 | $6.39 | $70,290.00 | | |
| 1/15/2014 | Enterprise Associates 13 L New | Major Shareholder | Buy | 512,500 | $8.00 | $4,100,000.00 | | |
| 1/15/2014 | M James Barrett | Director | Buy | 1,000,000 | $8.00 | $8,000,000.00 | | |
(Data available from 1/1/2013 forward)
GlycoMimetics (NASDAQ GLYC) News Headlines
| Source: |
|
GlycoMimetics (NASDAQ:GLYC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
GlycoMimetics (NASDAQ:GLYC) Income Statement, Balance Sheet and Cash Flow Statement
GlycoMimetics (NASDAQ GLYC) Stock Chart for Thursday, April, 19, 2018
Loading chart…
